Brii Builds China Ops With Hep B Assets, New Partnerships
Executive Summary
China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of deals with VBI and Vir for hepatitis B, and builds other alliances and operations in the country.
You may also be interested in...
Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push
The two companies have partnered on VBI-2601 since 2018, and Brii is now taking global rights to that program as well as licensing rights to VBI’s hepatitis B vaccine.
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.